Abstract
The introduction of total genome sequencing led to the confirmation that tumors show substantial genetic heterogeneity. This phenomenon, which describes the presence of different genetic cell clones within a tumor also complicates the diagnostics of HER2. This article gives a review of new knowledge on polysomy 17 and genetic tumor heterogeneity in connection with HER2 determination of breast cancer.
MeSH terms
-
Aneuploidy
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Breast / pathology
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology*
-
Chromosomes, Human, Pair 17 / genetics*
-
Female
-
Gene Expression Regulation, Neoplastic / genetics*
-
Genetic Heterogeneity*
-
Humans
-
In Situ Hybridization*
-
Polyribosomes / genetics*
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / genetics*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab